- Home
- SKYE vs ABOS Comparison
SKYE vs ABOS Comparison
Compare SKYE & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- ABOS
- Stock Information
- Founded
- SKYE 2012
- ABOS 1996
- Country
- SKYE United States
- ABOS United States
- Employees
- SKYE N/A
- ABOS N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- SKYE Health Care
- ABOS Health Care
- Exchange
- SKYE Nasdaq
- ABOS Nasdaq
- Market Cap
- SKYE 94.0M
- ABOS 99.1M
- IPO Year
- SKYE N/A
- ABOS 2021
- Fundamental
- Price
- SKYE $2.73
- ABOS $1.56
- Analyst Decision
- SKYE Buy
- ABOS Strong Buy
- Analyst Count
- SKYE 6
- ABOS 3
- Target Price
- SKYE $18.67
- ABOS $9.33
- AVG Volume (30 Days)
- SKYE 167.7K
- ABOS 379.4K
- Earning Date
- SKYE 02-09-2025
- ABOS 11-12-2024
- Dividend Yield
- SKYE N/A
- ABOS N/A
- EPS Growth
- SKYE N/A
- ABOS N/A
- EPS
- SKYE N/A
- ABOS N/A
- Revenue
- SKYE N/A
- ABOS N/A
- Revenue This Year
- SKYE N/A
- ABOS N/A
- Revenue Next Year
- SKYE N/A
- ABOS N/A
- P/E Ratio
- SKYE N/A
- ABOS N/A
- Revenue Growth
- SKYE N/A
- ABOS N/A
- 52 Week Low
- SKYE $2.25
- ABOS $1.54
- 52 Week High
- SKYE $19.41
- ABOS $5.09
- Technical
- Relative Strength Index (RSI)
- SKYE 37.40
- ABOS 30.29
- Support Level
- SKYE $2.31
- ABOS $1.69
- Resistance Level
- SKYE $3.04
- ABOS $1.88
- Average True Range (ATR)
- SKYE 0.30
- ABOS 0.13
- MACD
- SKYE 0.07
- ABOS -0.00
- Stochastic Oscillator
- SKYE 44.68
- ABOS 4.88
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.